HIV-1 Protease Inhibitors for Drug-Resistant Variant Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current HAART treatments for HIV/AIDS are limited by drug-resistant HIV-1 variants, toxicity, and complex regimens, failing to eradicate the virus due to residual viral reservoirs and immune reconstruction syndrome.

Innovation Solution

Development of potent HIV-1 protease inhibitors, including aspartyl protease inhibitors, which are 100-fold more potent than darunavir and effective against darunavir-resistant HIV-1 variants, administered alone or in combination with other antiretroviral drugs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If HAART treatment regimens are used to control HIV infection, then quality of life and HIV management are improved, but toxicity and regimen complexity increase

Engineering Contradiction:

ImproveHIV management effectivenessVSAvoidregimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines multiple antiretroviral drugs into a single fixed-dose combination pill containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate. This merging of multiple medications into one formulation directly reduces regimen complexity while maintaining comprehensive HIV management effectiveness.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The fixed-dose combination pill serves multiple functions simultaneously: it provides antiviral activity through three different mechanisms (efavirenz as NNRTI, emtricitabine and tenofovir as NRTIs), simplifies patient adherence by requiring only one pill, and addresses both treatment and prevention needs. This multi-functionality resolves the contradiction between comprehensive management and regimen simplicity.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Duration of action of stationary object

If HAART treatment is administered to prolong survival, then life extension is achieved, but drug-related toxicities and adverse effects increase

Engineering Contradiction:

Improvesurvival durationVSAvoiddrug toxicity

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical parameters of antiretroviral drugs by developing optimized formulations with improved pharmacokinetic properties. The fixed-dose combination uses specific dosage ratios and delivery mechanisms that enhance therapeutic efficacy while reducing toxic side effects compared to individual drug administrations.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The fixed-dose combination formulation acts as an intermediary system that delivers multiple drugs in controlled proportions. This intermediary approach ensures optimal plasma concentrations of each component drug, maximizing therapeutic benefit while minimizing toxic effects through balanced pharmacokinetic profiles.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If combination therapy with multiple drugs is used to combat HIV, then viral control is improved, but development of drug-resistant variants occurs

Engineering Contradiction:

Improveviral controlVSAvoiddrug resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The fixed-dose combination merges three antiretroviral drugs with different mechanisms of action (NNRTI and two NRTIs) into a single regimen. This combination approach creates multiple simultaneous barriers to viral replication, making it significantly harder for the virus to develop resistance compared to monotherapy or dual therapy.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

Each drug in the combination targets specific viral enzymes with different mechanisms: efavirenz inhibits reverse transcriptase through a non-nucleoside mechanism, while emtricitabine and tenofovir use nucleoside reverse transcriptase inhibition. This diversity of local mechanisms (different molecular targets and modes of action) prevents any single resistance mutation from compromising overall viral control.

Inventive Principle:

Principle #3Local quality

4Reliability

If intensive antiretroviral therapy is used to eradicate HIV, then viral suppression is improved, but immune re-construction syndrome and inflammation flare-up occur

Engineering Contradiction:

Improveviral suppressionVSAvoidinflammation flare-up

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The fixed-dose combination enables sustained periodic administration of antiretroviral therapy with optimized dosing intervals. This regular, controlled delivery maintains steady viral suppression while avoiding the abrupt immune reconstitution that triggers inflammatory flare-ups, by providing consistent rather than erratic drug levels.

Inventive Principle:

Principle #19Periodic action

Data Source

PatentEP3938371B1HIV-1 protease inhibitors and uses thereof

Publication Date: 2026.03.04 PURDUE RES FOUND

AI summary

Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof. The compounds disclosed herein are as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.